Given that emerging and clear evidence has shown PAPR1 inhibitors could improve the life quality for patients suffering cancer and cardiovascular diseases 43-45, multi-target therapeutic methods inhibiting PARP1 and activating C/EBPβ SUMOylation would be potential for treating pathological cardiac hypertrophy. The gene discussed is CEBPB; the disease is cardiovascular disorder.